| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | GDC-0449 | FIMM | pan-cancer | AAC | 0.019 | 0.9 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | ifosfamide | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | 0.015 | 0.9 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |